Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3191.

https://doi.org/10.1182/blood-2019-132204

Published: 2019

Journal Articles

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Malathi Kandarpa, PhD, Kristen Pettit, MD, Yi-Mi Wu, PhD, Qing Li, MD, Robert Lonigro, Dan Robinson, PhD, Luke F. Peterson, PhD, Philip S Boonstra, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2018) 132 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2018-99-113418

Published: 2018

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

Journal Articles

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Benjamin Garmezy, MD, Philip S Boonstra, PhD, Malathi Kandarpa, PhD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 2929.

https://doi.org/10.1182/blood.V130.Suppl_1.2929.2929

Published: 2017

Journal Articles

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Blood (2017) 130 (Supplement 1): 377.

https://doi.org/10.1182/blood.V130.Suppl_1.377.377

Published: 2017

Journal Articles

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

Kamal Menghrajani, MD, Philip S. Boonstra, PhD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Ruben A. Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz, MD

Blood (2016) 128 (22): 4270.

https://doi.org/10.1182/blood.V128.22.4270.4270

Published: 2016

Journal Articles

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Menghrajani Kamal, MD, Philip S. Boonstra, PhD, Alissa A. Weber, MD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Huong (Marie) Nguyen, MD, Ruben Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz

Blood (2014) 124 (21): 1842.

https://doi.org/10.1182/blood.V124.21.1842.1842

Published: 2014

NARROW

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Email alerts

ASH Publications

American Society of Hematology

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only